Evidence Supporting EMA Drug Approvals (2020-2023): A Cross-Sectional Study of Trial Design and Outcomes

BackgroundThe strength and transparency of clinical trial evidence supporting drug approvals has become increasingly scrutinized, particularly considering the increased use of regulatory flexibility and expedited pathways. While U.S. Food and Drug Administration (FDA) standards have been extensively analyzed, evidence standards at the European Medicines Agency (EMA) remain less well-characterized. Thus, this study aims to systematically assess the design, quality, and outcomes of pivotal efficacy trials supporting EMA drug approvals between 2020 and 2023. MethodsWe conducted a cross-sectional analysis of new medicines and biosimilars receiving positive opinions from the EMAs Committee for Medicinal Products for Human Use (CHMP) and subsequent approval by the European Commission between January 2020 and December 2023. Data were extracted from European Public Assessment Reports (EPARs) and EMA medicine databases. Key variables included trial design features, primary endpoint type and achievement status, and justification for approval in cases of failed efficacy endpoints. ResultsBetween 2020 and 2023, 232 drugs were approved by the EMA for 281 indications. Of these, 205 (88.4%) were new active substances and 65 (28.0%) were granted orphan designation. Forty-six products (19.8%) were approved via a special regulatory program, most commonly Conditional Approval (26 products; 11.2%). Cancer was the leading therapeutic area, accounting for 61 approvals (26.3%). Approvals were supported by 393 pivotal clinical trials. Of these, 327 (83.2%) were randomized controlled trials (RCTs) and 218 (66.6% of RCTs) had a superiority design. A total of 232/393 trials (59.0%) relied on surrogate endpoints. Overall, 22 approvals (9.5%) were supported by at least one pivotal trial in which at least one primary endpoint was not met; in seven of these cases (31.8%), the failed trial was the sole pivotal trial. The most common rationale for approval despite null primary results was reliance on the totality of evidence, secondary endpoints, or clinical judgment (9 products; 40.9%). ConclusionsOur findings reveal substantial variability in the design and evidentiary strength of pivotal trials supporting EMA approvals between 2020 and 2023. While the majority of studies were RCTs, reliance on surrogate endpoints was common. That 10% of approvals were based on pivotal trials with null primary endpoints highlights the nuanced role of regulatory judgment in therapeutic evaluation. These findings prompt reflection on evolving evidence standards in drug regulation and underscore the need for transparency and consistent justifications.